The Efficacy and Safety RC48 Plus QL1706 in Second-Line Treatment of HER2-Expressing Recurrent CC
Clinical trial NCT07172217 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07172217
- Sponsor
- Qilu Hospital of Shandong University
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-10-01
- Primary completion
- 2027-02-28
- Enrollment
- 33
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.